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To the Editor, Endoscopic biopsies are the mainstay of diagnosis in pediatric gastrointestinal (GI) diseases; yet, no formal study has examined the number of levels/sections submitted that are sufficient for the evaluation of GI biopsies. In majority of centers, this practice is experience based and highly dependent on the discretion of the pathologists. Although most GI pathology can be diagnosed on initial microscopic sections, some diseases such as inflammatory bowel disease (IBD) have focal lesions such as granulomas or giant cells that may require analysis of multiple sections for identification. In the pediatric population, the majority of these biopsies are performed for the diagnosis and surveillance of IBD, including Crohn's disease, which has at times minimal and focal histological changes including granulomas and/or giant cells. 1 At the Hospital for Sick Children, the traditional histological examination of endoscopic biopsies involved cutting 6 slides for each biopsy part, each containing a ribbon of 6-7 serial sections. Three of these slides (levels 1, 3, and 5) were stained with H&E and examined microscopically for surveillance. The remaining 3 slides (levels 2, 4, and 6) were stored for additional stains as necessary (eg, infectious stains and immunohistochemistry).
Over recent years, we have seen an exponential increase in our GI biopsy workload ( Figure 1 ) without a concomitant increase in staffing levels. As a result, the aim of this study was to determine whether we could decrease our workload without affecting the ability to detect focal lesions such as granulomas and giant cells, essentially using the principles of lean management systems to reduce overproduction and extra processing.
2 By using Crohn's disease as a model of a focal disease process, the findings could be used to rationalize a reduction in slides and workload for all GI biopsies. We sought to analyze whether examining only 2 slides (levels 3 and 5) would affect the ability of the pathologist to identify giant cells and granulomas in Crohn's disease.
Our database was searched for cases of granulomatous enterocolitis, gastritis, and esophagitis from 2012 to 2013. Archival slides were retrieved and 3 H&E-stained slides for each biopsy part (representing levels 1, 3, and 5) were examined. Biopsies containing giant cells or granulomas were identified and tabulated, noting the level within which granulomas were present. Twenty-eight consecutive cases of enterocolitis (n ¼ 25) and gastritis/esophagitis (n ¼ 3) with granulomas were identified and 189 biopsy parts (ie, a specific site of the GI tract such as cecum, ascending colon, etc) were reviewed. Ninetythree (49%) of 189 biopsy parts contained granuloma(s) and/or giant cell(s). Of those 93 biopsy parts, 90 (96.7 %) contained a granuloma and/or giant cell in either all levels or in level 3 or 5. Only 3 biopsy parts from 2 patients had granulomas on level 1 alone; however, both these patients had granulomas in levels 3 and/or 5 at other sites in the same series (see Table 1) . Thus, eliminating level 1 had no impact on identifying granulomas and giant cells and thereby on the diagnosis of IBD.
By reducing the number of examined slides from 3 to 2 for each biopsy part, we significantly reduced the number of slides cut and examined without affecting the pathologist's ability to reach a diagnosis. Furthermore, extrapolating the change to all GI biopsies in general resulted in a saving of approximately 7500 slides/year and a reduction in workload approximating to 4 h/week for the pathologist (Figure 2) . By sharing our experience, we endeavor to provide a guideline to pediatric GI pathologists with regard to number of microscopic sections/levels sufficient for diagnosis. The findings from this study can be used to rationalize a reduction in slides and workload for all GI biopsies. Figure 2 . Reduction in workload using the new GI protocol for the laboratory (top) and pathologists (bottom), based on 2012 numbers (see also Table 1 ).
